Stephen Sullivan has been Chairman of Firma Clinical Research since January of 2016 when Thompson Street Capital Partners made its investment in H2O Clinical. Mr. Sullivan also led the acquisition of Pharma Start and the rebranding process to form Firma Clinical Research. He is also the founder of CRO Advisors LLC and has advised TSCP on several acquisitions and integrations. He brings over 18 years of pharma service experience as head of Covance Clinical Services from 1999-2006 and CEO of Harlan Laboratories from 2006 to 2010. Previously, he was Chairman and CEO of Xenometrix, a biotech company, and spent many years in senior management positions at Abbott Laboratories. Mr. Sullivan is an Adjunct Professor at Georgetown University where he created and teaches the course “Drug Development from Discovery to Post-approval” in the Masters of Biotechnology Program. Mr. Sullivan is a former Marine Officer and received his BS from the University of Dayton and MBA from Rutgers University.
Dr. Christina Fleming assists in providing Firma’s strategic direction by leveraging her 20+ years of biopharmaceutical and clinical research organization (CRO) industry experience. Her experience includes building, managing and leading the clinical development, medical writing, and pharmacovigilance divisions at Searle (formerly Pharmacia, now Pfizer), TAP (now Takeda), Neopharm, Inc., and Baxter Healthcare as well as developing the outsourcing and consulting services at several CROs. This experience led her to create and develop Pharma Start into a highly successful and unique outsourcing organization. Pharma Start merged with H2O Clinical in 2016 and was rebranded to Firma Clinical Research in 2017.
Dr. Fleming is a 2010 recipient of PharmaVoice’s Top 100 Most Inspiring People in the Life Sciences Industry award and is a member of DIA, AMWA, and RAPS. Dr. Fleming earned her Bachelor of Science (BS) in Biology at Saint Mary’s College and her Doctor of Philosophy (Ph.D.) in Pharmacology from the University of Illinois at Chicago.
Dr. Henry brings more than 29 years of both hands-on and senior level clinical research experience in large pharmaceutical, biotechnology and contract research organizations. Eugenia has served as a statistical consultant and DMC member for many clients and has vast experience in communicating with the FDA for design and statistical issues. To date, Dr. Henry has been actively involved in 56 NDA/sNDA/ANDA/PMA submissions with 52 approvals.
Dr. Henry has leveraged her extensive expertise to create successful data management and statistical services companies such as HHI Clinical Research and Statistical Services which was sold to InVentiv in 2004. Dr. Henry then co-founded H2O Clinical Research in 2011 which merged with Pharma Start in 2016 and was rebranded to Firma Clinical Research in 2017. She has also served in similar roles at Pfizer as the head of Biostatistics and Data Management for the Department of Clinical Pharmacology and Experimental Medicine and at Novartis as the head of Biostatistics and Data Management for Medical Affairs. Dr. Henry received her Ph.D. in Biostatistics from the University of Missouri, Columbia.
As the company’s Chief Medical Officer, Dr. Henry will provide leadership and direction for Firma’s clinical development programs.
In 2011, Dr. Henry co-founded H2O Clinical which was rebranded to Firma Clinical Research in 2017. Prior to H2O, Dr. Henry served as the co-Chief Medical Officer of InVentiv Health and Chief Medical Officer of InVentiv Clinical Solutions.
Before InVentiv, Dr. Henry was Head of Clinical Research and Regulatory Affairs at Cephalon, Inc., Head of Clinical Research at Guilford Pharmaceuticals, and Global Head of Central Nervous System Clinical Research at the Sandoz Research Institute. Dr. Henry started his pharmaceutical career at Pfizer Central Research.
Dr. Henry received his medical degree from the University of Chicago (Pritzker) School of Medicine and his bachelor’s degree in Chemistry from the University of Illinois. He was a medical intern at the University of Chicago Hospitals and Clinics and trained in neurology and neuropathology at the Longwood Neurology Program in Boston, which included the Peter Bent Brigham Hospital, Beth Israel Hospital, and Boston Children’s Hospital. Prior to joining Pfizer, Dr. Henry was on staff at Boston Children’s Hospital and Harvard Medical School.
Mr. Keens serves as Chief Commercial Officer for Firma Clinical Research, leading the Business Development, Proposals, and Marketing teams. He has extensive experience within the industry, including roles in Clinical Operations, Project Management, Consulting, and Business Development leadership across both large global and growing CROs. Mr. Keens leverages his knowledge and landscape experience to help Biotech and Pharmaceutical Sponsors identify project/program needs and examine how Firma may deploy expertise and resources to support these needs to achieve their drug development goals. Mr. Keens earned his undergraduate degree in Biology/Psychology from James Madison University, and his Master’s degree in Public Health from The University of Virginia.
Mark Ubert serves as Chief Financial Officer and provides leadership to several functional areas within the organization. He has provided executive financial experience in a variety of roles and industries, bringing more than 30 years of experience to his role with Firma Clinical.
His career in the CRO industry began in 1999 and has had continuous involvement in a financial leadership capacity since. Mr. Ubert joined Quintiles in 1999 assuming the Head of Finance for the KC, MO office. In 2001, he accepted an opportunity to provide financial leadership to the Quintiles operations in Asia, while based in Tokyo. In 2006, he became the Finance Leader for Quintiles Global Data Management. Mark holds a BBA degree in accounting from Washburn University and MBA degree, with emphasis in Finance, from Keller Graduate School. He obtained his designation as a certified public accountant in 1983.
Kimberly Finn brings 22 years of pharmaceutical and CRO industry experience to Firma. She began her career as a CRA and assumed roles of increasing responsibility within clinical operations and project management with expertise in therapeutic areas including: cardiovascular and metabolic disorders, blood and lymphatic system disorders, CNS, oncology, immunology and vaccines. In addition, she has facilitated the successful delivery of portfolios valued at greater than $100 million and contributed to the development of five NDA approved and marketed compounds. In her role as head of clinical operations and remote visit services, she brings strategic and operational expertise to both departments focusing on global project excellence. Ms. Finn earned her Bachelor of Science degree in Biology from the University of Illinois at Urbana-Champaign.
Matt Scherrer has been a member of the Board at Firma Clinical Research since January of 2016. He is a Managing Director at Thompson Street Capital Partners where he leads investments in healthcare services. Mr. Scherrer has been at Thompson Street since 2007. Previously, he served in the US Army as an Infantry officer. He holds an undergraduate degree from Princeton University and an MBA from Harvard Business School.